Why should flecainide be discontinued in a patient with atrial fibrillation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Why Flecainide Should Be Stopped in Atrial Fibrillation

Flecainide must be discontinued immediately if a patient develops structural heart disease, coronary artery disease, heart failure with reduced ejection fraction (LVEF <35-40%), significant conduction abnormalities (QRS widening >25% from baseline), or ventricular arrhythmias, as continuation poses life-threatening risks of ventricular proarrhythmia and sudden cardiac death. 1, 2

Primary Reasons for Discontinuation

Structural Heart Disease or Coronary Artery Disease

  • Flecainide is absolutely contraindicated in patients with coronary artery disease or structural heart disease due to increased mortality risk demonstrated in the landmark CAST trial 1
  • The CAST trial showed flecainide increased mortality (5.1% vs 2.3% placebo) and cardiac arrest rates in post-MI patients 2
  • The mechanism is ventricular proarrhythmia—specifically monomorphic ventricular tachycardia (not torsades de pointes) 1
  • Risk is highest with ventricular conduction delays (QRS >120ms), ventricular scar tissue, or left ventricular dysfunction 1

Heart Failure with Reduced Ejection Fraction

  • Flecainide is contraindicated when LVEF falls below 35-40% 1, 3, 2
  • The drug has potent negative inotropic effects that can precipitate or worsen heart failure 1, 2
  • In clinical trials, 7.7% of patients developed worsened CHF, with onset ranging from hours to months after starting therapy 2
  • If heart failure develops during treatment, flecainide must be discontinued or dose-reduced, with optimization of other heart failure therapies 2

Dangerous Conduction Abnormalities

Stop flecainide if any of these ECG changes occur 4, 2:

  • QRS widening ≥25% from baseline (sign of potential proarrhythmia requiring immediate discontinuation or dose reduction)
  • Second-degree or third-degree AV block develops
  • Right bundle branch block with left hemiblock appears
  • New bundle branch block emerges
  • Sinus node dysfunction (sinus pause, arrest, symptomatic bradycardia)

Conversion to Atrial Flutter with Rapid Ventricular Response

  • Flecainide can convert atrial fibrillation to atrial flutter with paradoxically faster 1:1 AV conduction 4, 2, 5
  • This occurs because flecainide slows the atrial rate enough to allow 1:1 conduction through the AV node
  • This is a medical emergency requiring immediate discontinuation
  • Prevention requires concomitant AV nodal blockade (beta-blockers or calcium channel blockers) 4

Chronic Atrial Fibrillation

  • Flecainide is NOT recommended for chronic (permanent) atrial fibrillation 2
  • Literature review showed 10.5% of chronic AF patients experienced ventricular tachycardia or ventricular fibrillation 2
  • The drug is appropriate only for paroxysmal or persistent AF with rhythm control strategy 6

Additional Reasons for Discontinuation

Renal Dysfunction

  • Flecainide is renally cleared; acute kidney injury causes drug accumulation and toxicity 7
  • Toxicity can manifest as encephalopathy, visual hallucinations, bradycardia, and conduction abnormalities 7
  • Dose adjustment or discontinuation required with declining renal function

Adverse Effects Requiring Cessation

Common reasons patients stop flecainide 5, 8:

  • Proarrhythmic effects (most common cardiac reason—48% of discontinuations in one study) 8
  • Dizziness (15-20%)
  • Visual disturbances (blurred vision, difficulty focusing—up to 15%)
  • Gastrointestinal complaints
  • Bradyarrhythmias
  • Suspected ventricular proarrhythmia

Inefficacy

  • Approximately 50% of patients show clinical efficacy with long-term use 8
  • Insufficient symptom control is a valid reason to discontinue and consider alternative therapies (catheter ablation, different antiarrhythmic) 3, 8

Critical Monitoring Parameters

Before continuing flecainide, verify:

  • No structural heart disease (echocardiogram showing normal LVEF and no significant LV hypertrophy)
  • No coronary artery disease (stress test in patients >50 years or with cardiac risk factors) 3
  • Baseline ECG with QRS <120ms
  • Normal renal function
  • Concomitant AV nodal blocking agent prescribed 4, 3

During therapy, discontinue if:

  • QRS widens ≥25% from baseline 4, 2
  • New conduction abnormalities develop
  • Heart failure symptoms emerge
  • Plasma levels exceed 0.7-1.0 mcg/mL (when measurable) 4, 2

Common Pitfalls to Avoid

  1. Never continue flecainide if ischemic heart disease is discovered—even if previously well-tolerated 4, 1
  2. Don't use flecainide without AV nodal blockade—risk of 1:1 atrial flutter conduction 4
  3. Don't ignore QRS widening—this is your warning sign of impending proarrhythmia 4, 2
  4. Don't assume "no symptoms" means "safe"—CAST trial patients were asymptomatic yet had increased mortality 2
  5. Don't use in chronic/permanent AF—only for paroxysmal/persistent AF with rhythm control strategy 2

The most recent and comprehensive guidelines 6 confirm: "Flecainide or propafenone is recommended in patients with AF requiring long-term rhythm control to prevent recurrence and progression of AF, excluding those with impaired left ventricular systolic function, severe left ventricular hypertrophy, or coronary artery disease."

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.